HP and chronic kidney disease: Second, α-klotho exogenous supplementation and/or upregulation or restoration of α-klotho by reducing the iron levels via chelating agent or dietary iron restriction may provide novel therapy for DN patients with Hp 2-2 genotype to retard or block its progression to advanced CKD by arresting or slowing progression as well as by preventing and reversing complications [33].